Safer Medications for Children and Youth

Last modified by Paula Robeson on 2019/09/27 15:43

Raising the Bar: the Path to Safer Medications for Canadian Children

Children, like adults, have a right to the highest attainable standard of health, which includes the appropriate treatment of disease.  Yet children and youth continue to be under-represented in medication research, as well as the design of medication-related regulations and commercial medication development.

Up to 80% of all medications currently prescribed in Canadian paediatric hospital settings are administered off-label, meaning that the use deviates from the dose, route of administration, patient age and or medical indication in the Health Canada-approved monograph.  Moreover, many commonly prescribed pediatric medications cannot be dispensed as commercially available child-friendly formulations (i.e. a liquid or a low-dose mini-tab). Both practices are associated with significant risk, including adverse events, safety issues and efficacy concerns for children and youth.

This webinar will provide an in-depth overview of the current state of Pediatric Medications in Canada.  Panelists will discuss access barriers, opportunities such as a National Pharmacare Plan as well as recommendations regarding pediatric drug research and the drug regulatory system in Canada.  Advocating to improve the health outcomes of children and youth is imperative, please join the discussion.

Election 2019 - Getting Kids Back on the Radar -This webinar is part of a 4-part series highlighting Children's Healthcare Canada's activities related to the upcoming 2019 federal election.  For more information on this series, click here.  The 2019 federal election is an opportunity to #StandUpforKids and advance policy priorities which will directly impact health services delivery and health outcomes for Canada’s children and youth.  Children's Healthcare Canada is committed to supporting our members in your interactions with potential candidates.  Click here for tools and resources that may be helpful to you in your interactions with the different candidates during this election season.

20161215-GBP-Bob-Connelly-square.jpgDr. Robert (Bob) Connelly

Dr. Connelly is a neonatologist, medical educator, and the Head of Pediatrics at Queen's University.His particular interest is in resident assessment, particularly the use of rubrics as assessment tools and improving patient safety through the use of structured hand off tools. He has served as Pediatric Residency Program Director and was a member of the Pediatric Exam Committee and Chair of the MCQ Test Committee at the Royal College of Physicians and Surgeons. He remains active as a participant in the Competency By Design team for Pediatrics and as the Vice Chair of the Specialty Committee for Neonatal-Perinatal Medicine.Bob is also interested in design thinking, whether it is to deliver a more compelling presentation or improving patient care. He is a self-described “geek wannabe” and is constantly on the lookout for new mobile technologies to improve productivity. He is an avid consumer of social media (meaning he spends too much time on Twitter) and is particularly focused on how it can be used in medical education.

Andrea Gilpin 0984Final A_2 3 Hi Res.jpgDr. Andrea Gilpin

Dr. Gilpin is the General Manager of the Goodman Pediatric Formulations Centre of the CHU Sainte-Justine. Dr. Gilpin began her career as a bench scientist and completed her Doctorate in Molecular Biology and Biochemistry from the University of Toronto. Since that time, her career has brought her through several different roles. She left the lab to obtain an MBA in International Business and then worked for over 12 years in small biotechnology companies. After obtaining her MBA, she started in in business development and moved into investor relations and communications in various small biotechnology companies. She was Vice-President of Investor Relations and Communications at Theratechnologies when she decided, in 2010, to gain pharmaceutical experience and joined the Communications team at Pfizer. In 2012, she took on the role of Head of Corporate Communications for Novartis Canada. With a desire to gain commercial experience, in 2015, she moved to a marketing oncology position in the Lung and Melanoma franchise at Novartis. For more please visit her LinkedIn profile.

charlotte biopic.jpgDr. Charlotte Moore Hepburn

Dr. Moore Hepburn is a faculty paediatrician in the Division of Paediatric Medicine at the Hospital for Sick Children and an associate professor of Paediatrics in the Department of Paediatrics at the University of Toronto School of Medicine.  She also has the honour of serving as the Director of Medical Affairs for the Canadian Paediatric Society, and the Director of Medical Affairs for the Canadian Paediatric Surveillance Program.

Tags:
Created by Ann Watkins on 2019/08/15 15:57